A special purpose acquisition company, known colloquially as a blank cheque company, has been launched by Life Sciences Partners (LSP) of the Netherlands, the first such company to focus exclusively on European biotech. Special purpose acquisition companies, or SPACs, are proliferating on Wall Street, fuelled by low interest rates and a demand from investors for innovative assets.
